The abstract is read at the publisher; the summary is JClub's.
Three cryo-EM structures of RXFP1 show divergent activation: relaxin-2 binds the ectodomain and reorganizes the linker into a helical structure, while AZD5462 binds the transmembrane domain and stabilizes a distinct active conformation.
- Why it matters: RXFP1 is a therapeutic target for fibrosis and heart failure, and midstage clinical protein and small-molecule agonists for heart disease need mechanistic clarification.
- What they did: The authors solved cryo-electron microscopy structures of ligand-free RXFP1, RXFP1 bound to relaxin-2, and RXFP1 bound to AZD5462, then used hydrogen-deuterium exchange mass spectrometry to map domain and conformational changes.
- The result: Relaxin-2 induces linker-domain helical secondary structure, whereas AZD5462 stabilizes an active conformation via different rearrangements, defining distinct activation mechanisms for RXFP1 agonists.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.